Physician profile
Doyle D Stephens
NPI 1114147097
$3,635.02
in general payments reported to CMS, 2019-2025
32 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $217 · 2021: $698 · 2022: $734 · 2023: $607 · 2024: $683 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $707.67 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $491.94 | 2019-2024 | Xtandi |
| Endo Pharmaceuticals INC. | $300.38 | 2019-2024 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $278.88 | 2019-2024 | |
| Urovant Sciences INC | $203.58 | 2021-2022 | |
| Pfizer INC. | $182.38 | 2019-2025 | |
| Allergan, INC. | $173.25 | 2019-2022 | |
| Medtronic, INC. | $140.95 | 2021-2025 | Interstim |
| Myriad Genetic Laboratories, INC. | $120.35 | 2021-2024 | Prolaris |
| Urogen Pharma, INC. | $108.21 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $103.72 | 2021 | |
| Axonics, INC. | $80.95 | 2020-2024 | Axonics, Bulkamid |
| Janssen Biotech, INC. | $79.35 | 2022 | |
| Olympus America INC. | $68.33 | 2022-2025 | Itind System, Uretero-Reno Videoscope, Cysto-Nephro Videoscope |
| Abbvie INC. | $68.31 | 2019-2025 | Botox |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $62.91 | 2024 | Xiaflex |
| Coloplast Corp | $59.67 | 2019-2022 | |
| Boston Scientific Corporation | $57.17 | 2019-2023 | Spaceoar Vue System - 10ml |
| Procept Biorobotics Corporation | $45.19 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Progenics Pharmaceuticals, INC. | $42.71 | 2023-2025 | Pylarify |
| Tolmar Pharmaceuticals, INC. | $42.00 | 2019 | |
| Hollister Incorporated | $27.87 | 2022 | |
| Travere Therapeutics, INC. | $26.57 | 2020-2021 | |
| Blue Earth Diagnostics | $25.56 | 2021 | |
| Ferring Pharmaceuticals INC. | $22.72 | 2025 | Adstiladrin |
| Rochester Medical Corporation | $18.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.99 | 2025 | |
| Mission Pharmacal Company | $17.42 | 2019 | |
| Myovant Sciences INC. | $16.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.96 | 2025 | Erleada |
| Therapeuticsmd, INC. | $13.73 | 2019 | |
| Verity Pharmaceuticals INC. | $13.72 | 2025 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doyle Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.